DexCom Reports Theft of Condemned G7 Devices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2026
0mins
Source: NASDAQ.COM
- Theft Incident: DexCom reported the theft and resale of two condemned lots of G7 devices, which are unfit for patient use and pose an increased risk of skin infections, potentially damaging the company's reputation and customer trust.
- Testing Failure Rate: An elevated internal testing failure rate in one of the lots may result in no sensor readings, raising further concerns about patient safety and potentially impacting future sales and market share.
- Supply Chain Alert: DexCom has warned vendors who purchased devices from Pharmsource LLC, emphasizing the company's commitment to product safety while notifying affected customers to mitigate potential legal liabilities.
- Stock Price Reaction: Despite the negative news surrounding the theft, DexCom's stock price rose slightly by 0.33%, currently trading at $72.33, indicating some market confidence in the company's long-term outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 71.230
Low
68.00
Averages
82.54
High
100.00
Current: 71.230
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Model: Abbott operates across four major segments—medical devices, diagnostics, nutrition, and established pharmaceuticals—reporting $5.5 billion in medical device revenue in Q1 2023, which constitutes about 50% of total sales, showcasing resilience in changing healthcare and economic environments.
- Diabetes Care Growth: The FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales with over 7 million users globally, and with diabetes prevalence expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Boost: Abbott's cardiovascular segment achieved around $578 million in Q1 revenue, with products like MitraClip and TriClip capturing an increasing share of the minimally invasive heart repair market, which is projected to expand significantly over the next decade.
- Steady Revenue Streams: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Glucerna providing recurring revenue that helps offset fluctuations in other business areas.
See More
Abbott's Diversified Business Fuels Growth
- Medical Device Growth: Abbott's medical device segment generated approximately $5.5 billion in revenue during Q1, accounting for nearly half of the company's total sales, showcasing its strong competitive position and market demand in the healthcare sector.
- Diabetes Monitoring Success: The FreeStyle Libre continuous glucose monitoring platform achieved around $2 billion in sales in Q1, with over 7 million users globally, indicating Abbott's significant presence in the rapidly growing diabetes care market.
- Cardiovascular Business Contribution: Abbott's cardiovascular segment reported approximately $578 million in revenue from structural heart products in Q1, with analysts expecting significant market expansion over the next decade due to aging populations, further driving the company's growth.
- Stable Revenue Streams: Abbott's diagnostics and nutrition segments generated about $2.1 billion and $2 billion in sales respectively during Q1, ensuring stability in fluctuating markets and providing funding for future innovation investments.
See More
FDA Approves DexCom's OTC Glucose Monitor for Children
- FDA Approval: The US FDA has approved DexCom's Stelo continuous glucose monitor for children aged two and older, marking it as the first OTC CGM approved for pediatric use, which is expected to significantly enhance DexCom's market share in children's diabetes management.
- Product Features: Stelo features a wearable sensor that provides glucose data every 15 minutes, with a sensor replacement every 15 days, offering a convenient monitoring solution that will help parents manage their children's diabetes more effectively.
- Market Potential: With the launch of Stelo, DexCom can meet the growing demand among pediatric diabetes patients, which is anticipated to drive revenue growth and further solidify its leadership position in the medical device market.
- Technological Innovation: Stelo not only enhances the convenience of diabetes monitoring but also improves user experience through its pairing with a smartphone app, potentially attracting more families to choose DexCom's products.
See More
Dexcom CONNECT Trial Significantly Improves Glucose Control in Type 2 Diabetes Patients
- Clinical Significance: The CONNECT randomized controlled trial demonstrated that participants using Dexcom G7 experienced an average A1C reduction of 1.6%, decreasing from a baseline of 8.8% to 7.2%, indicating its effectiveness in Type 2 diabetes management and potential to establish CGM as a new global standard of care.
- Combination Therapy Benefits: The study revealed that using Dexcom G7 in conjunction with various diabetes medications, including metformin, GLP-1s, and SGLT2s, resulted in a more significant A1C reduction, particularly for patients with initial A1C levels over 10%, who saw an average decrease of 3.1%, highlighting its additive therapeutic value.
- Improved Time in Range: Participants using Dexcom G7 spent an average of five more hours per day in the target glucose range compared to the control group, achieving 62% time in range at 26 weeks, which significantly enhances patient quality of life and satisfaction, underscoring its importance in daily diabetes management.
- Education and Support: All participants received education on diet and exercise at the study's outset, ensuring comprehensive support, and the 97% daily usage rate of Dexcom G7 further demonstrates its acceptability and practicality in patients' everyday lives.
See More
Dexcom CONNECT Trial Significantly Improves Glucose Control in Type 2 Diabetes Patients
- Clinical Trial Results: The CONNECT randomized controlled trial demonstrated that Dexcom G7 led to a significant average reduction of 1.6% in A1C, which is 0.9% greater than the control group, potentially establishing a new standard of care for Type 2 diabetes management globally.
- Combination Therapy Impact: Participants using Dexcom G7 in conjunction with various diabetes medications, including metformin, GLP-1s, and SGLT2s, experienced a clinically significant A1C reduction, particularly those with initial A1C levels above 10%, who saw an average decrease of 3.1%, highlighting its additive benefits across treatment regimens.
- Improved Time in Range: Patients using Dexcom G7 achieved an average of five additional hours per day in the glucose target range, reaching 62% time in range at 26 weeks compared to 41% in the control group, indicating its effectiveness in enhancing patient quality of life.
- Increased Patient Satisfaction: Participants reported higher satisfaction with Dexcom G7 compared to self-monitoring blood glucose, with a median daily usage rate of 97% throughout the 26-week study, underscoring its significance in daily diabetes management.
See More
Competitive Analysis of Diabetes Monitoring Market
- DexCom Financial Performance: In FY 2025, DexCom achieved nearly $4.7 billion in revenue, a 15.6% increase, with a net income of approximately $836.3 million and a net margin of 17.9%, indicating strong growth potential in the continuous glucose monitoring market.
- Insulet Market Position: Insulet generated over $2.7 billion in revenue in FY 2025, representing a 30.9% growth, with a net income of about $354.4 million and a net margin close to 10.4%, demonstrating its leadership and market expansion capabilities in the tubeless insulin pump sector.
- Competitive Risk Analysis: DexCom faces intense competition from large medical technology firms and is navigating a March 2025 FDA warning letter, which could impact its market performance, while Insulet's reliance on a single Omnipod product platform exposes it to risks from shifts in consumer preferences.
- Future Growth Potential: Despite the rise of GLP-1 drugs potentially affecting demand for both companies' products, the ongoing need for diabetes monitoring and treatment remains strong, with both DexCom and Insulet seeking to leverage technological innovation and market expansion to capture future growth opportunities.
See More
Abbott's Q2 Earnings Preview and Growth Drivers
- Diversified Business Model: Abbott operates across four major segments—medical devices, diagnostics, nutrition, and established pharmaceuticals—reporting $5.5 billion in medical device revenue in Q1 2023, which constitutes about 50% of total sales, showcasing resilience in changing healthcare and economic environments.
- Diabetes Care Growth: The FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales with over 7 million users globally, and with diabetes prevalence expected to exceed 850 million by 2050, Abbott has significant growth potential in this area.
- Cardiovascular Business Boost: Abbott's cardiovascular segment achieved around $578 million in Q1 revenue, with products like MitraClip and TriClip capturing an increasing share of the minimally invasive heart repair market, which is projected to expand significantly over the next decade.
- Steady Revenue Streams: Abbott's diagnostics and nutrition segments produced approximately $2.1 billion and $2 billion in Q1 sales, respectively, with brands like Ensure and Glucerna providing recurring revenue that helps offset fluctuations in other business areas.
See More
Abbott's Diversified Business Fuels Growth
- Medical Device Growth: Abbott's medical device segment generated approximately $5.5 billion in revenue during Q1, accounting for nearly half of the company's total sales, showcasing its strong competitive position and market demand in the healthcare sector.
- Diabetes Monitoring Success: The FreeStyle Libre continuous glucose monitoring platform achieved around $2 billion in sales in Q1, with over 7 million users globally, indicating Abbott's significant presence in the rapidly growing diabetes care market.
- Cardiovascular Business Contribution: Abbott's cardiovascular segment reported approximately $578 million in revenue from structural heart products in Q1, with analysts expecting significant market expansion over the next decade due to aging populations, further driving the company's growth.
- Stable Revenue Streams: Abbott's diagnostics and nutrition segments generated about $2.1 billion and $2 billion in sales respectively during Q1, ensuring stability in fluctuating markets and providing funding for future innovation investments.
See More
FDA Approves DexCom's OTC Glucose Monitor for Children
- FDA Approval: The US FDA has approved DexCom's Stelo continuous glucose monitor for children aged two and older, marking it as the first OTC CGM approved for pediatric use, which is expected to significantly enhance DexCom's market share in children's diabetes management.
- Product Features: Stelo features a wearable sensor that provides glucose data every 15 minutes, with a sensor replacement every 15 days, offering a convenient monitoring solution that will help parents manage their children's diabetes more effectively.
- Market Potential: With the launch of Stelo, DexCom can meet the growing demand among pediatric diabetes patients, which is anticipated to drive revenue growth and further solidify its leadership position in the medical device market.
- Technological Innovation: Stelo not only enhances the convenience of diabetes monitoring but also improves user experience through its pairing with a smartphone app, potentially attracting more families to choose DexCom's products.
See More
Dexcom CONNECT Trial Significantly Improves Glucose Control in Type 2 Diabetes Patients
- Clinical Significance: The CONNECT randomized controlled trial demonstrated that participants using Dexcom G7 experienced an average A1C reduction of 1.6%, decreasing from a baseline of 8.8% to 7.2%, indicating its effectiveness in Type 2 diabetes management and potential to establish CGM as a new global standard of care.
- Combination Therapy Benefits: The study revealed that using Dexcom G7 in conjunction with various diabetes medications, including metformin, GLP-1s, and SGLT2s, resulted in a more significant A1C reduction, particularly for patients with initial A1C levels over 10%, who saw an average decrease of 3.1%, highlighting its additive therapeutic value.
- Improved Time in Range: Participants using Dexcom G7 spent an average of five more hours per day in the target glucose range compared to the control group, achieving 62% time in range at 26 weeks, which significantly enhances patient quality of life and satisfaction, underscoring its importance in daily diabetes management.
- Education and Support: All participants received education on diet and exercise at the study's outset, ensuring comprehensive support, and the 97% daily usage rate of Dexcom G7 further demonstrates its acceptability and practicality in patients' everyday lives.
See More
Dexcom CONNECT Trial Significantly Improves Glucose Control in Type 2 Diabetes Patients
- Clinical Trial Results: The CONNECT randomized controlled trial demonstrated that Dexcom G7 led to a significant average reduction of 1.6% in A1C, which is 0.9% greater than the control group, potentially establishing a new standard of care for Type 2 diabetes management globally.
- Combination Therapy Impact: Participants using Dexcom G7 in conjunction with various diabetes medications, including metformin, GLP-1s, and SGLT2s, experienced a clinically significant A1C reduction, particularly those with initial A1C levels above 10%, who saw an average decrease of 3.1%, highlighting its additive benefits across treatment regimens.
- Improved Time in Range: Patients using Dexcom G7 achieved an average of five additional hours per day in the glucose target range, reaching 62% time in range at 26 weeks compared to 41% in the control group, indicating its effectiveness in enhancing patient quality of life.
- Increased Patient Satisfaction: Participants reported higher satisfaction with Dexcom G7 compared to self-monitoring blood glucose, with a median daily usage rate of 97% throughout the 26-week study, underscoring its significance in daily diabetes management.
See More
Competitive Analysis of Diabetes Monitoring Market
- DexCom Financial Performance: In FY 2025, DexCom achieved nearly $4.7 billion in revenue, a 15.6% increase, with a net income of approximately $836.3 million and a net margin of 17.9%, indicating strong growth potential in the continuous glucose monitoring market.
- Insulet Market Position: Insulet generated over $2.7 billion in revenue in FY 2025, representing a 30.9% growth, with a net income of about $354.4 million and a net margin close to 10.4%, demonstrating its leadership and market expansion capabilities in the tubeless insulin pump sector.
- Competitive Risk Analysis: DexCom faces intense competition from large medical technology firms and is navigating a March 2025 FDA warning letter, which could impact its market performance, while Insulet's reliance on a single Omnipod product platform exposes it to risks from shifts in consumer preferences.
- Future Growth Potential: Despite the rise of GLP-1 drugs potentially affecting demand for both companies' products, the ongoing need for diabetes monitoring and treatment remains strong, with both DexCom and Insulet seeking to leverage technological innovation and market expansion to capture future growth opportunities.
See More
